Our study, driven by data on the transcriptional and proteomic impacts of the BETi Birabresib on GBM, reports a combined sequential inhibition strategy targeting BET and PARP, which reduces toxicity without compromising therapeutic efficacy. The gene discussed is PARP1; the disease is glioblastoma.